MET is overexpressed in various solid tumors (eg. small cell lung cancer, non-small cell lung cancer, gastric cancer, renal cell carcinoma, and breast cancer)[6], [13]–[17] and its overexpression is often associated with an aggressive phenotype and poor prognosis. The gene discussed is MET; the disease is non-small cell lung carcinoma.